Levofloxacin sodium
Based on 32 publication(s) in Google Scholar
Levofloxacin ((-)-Ofloxacin) sodium is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin sodium inhibits the DNA gyrase and topoisomerase IV. Levofloxacin sodium can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin sodium shows anti-orthopoxvirus activity.
For research use only. We do not sell to patients.
- CAS No.: 872606-49-0
- Formula: C18H19FN3NaO4
- Molecular Weight:383.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Levofloxacin sodium
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2025 May 10;16(1):4366. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Chem Eng J. 2026 Feb 12.
- EBioMedicine. 2025 May 30:117:105776. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Clin Chem. 2019 Dec;65(12):1522-1531. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Int J Antimicrob Agents. 2025 Jun 9:107551. [Abstract]
- Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01921-20. [Abstract]
- Results Chem. 2024 Oct.
- Toxics. 2025 Feb 5;13(2):122. [Abstract]
- Microbiol Spectr. 2025 Oct 15:e0122125. [Abstract]
- Microbiol Spectr. 2025 May 19:e0307424. [Abstract]
- ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- Water. 2025 Jun 6.
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- PLoS One. 2024 Apr 18;19(4):e0298577. [Abstract]
- Future Microbiol. 2025 Oct 13:1-10. [Abstract]
- Chin J Traumatol. 2024 Jul 3:S1008-1275(24)00075-0. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- Res Sq. 2026 Mar 9.
- SSRN. 2025 Oct 14.
- Res Sq. 2025 Aug 05.
- bioRxiv. 2025 January 19.
- bioRxiv. 2024 May 10.
Customer Validation & Images
-
Microbiological Assay
-
Microbiological Assay
-
Cell Proliferation/Viability Assay
-
Microbiological Assay
-
Microbiological Assay
All Antibiotic Isoforms
MoreAll DNA/RNA Synthesis Isoforms
MoreAll Topoisomerase Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 872606-49-0
-
Molecular Weight 383.35
-
Formula C18H19FN3NaO4
-
SMILES
O=C1C2=CC(F)=C(N3CCN(CC3)C)C4=C2N(C=C1C(O[Na])=O)[C@@H](C)CO4
-
Synonyms
(-)-Ofloxacin sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Commun
Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours. [Abstract]2025 May 10;16(1):4366. PMID: 40348759
Levofloxacin sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]
M. bovis BCG Russia WT in LFX (0-25 h) 1 mg/L.
Levofloxacin sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]
M. bovisBCG Russia FQR in LFX (0-25 h) 1 mg/L.
-
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334
Levofloxacin sodium purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
Levofloxacin exhibited toxicity at 25 × Cmax, which resulted in a 65% reduction in organoid cell viability.
-
-
EBioMedicine
Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]2025 May 30:117:105776. PMID: 40449326
Levofloxacin sodium purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2025 May 30:117:105776. [Abstract]
Killing curves of different Ms rpoB mutants after exposure to LFX (0-48 h) at 1 μg/mL (5 × MIC) in 7H9 medium.
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Clin Chem
Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]2019 Dec;65(12):1522-1531. PMID: 31578215 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
Commun Biol
The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]2025 Oct 6;8(1):1425. PMID: 41053365 -
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Jun 9:107551. PMID: 40499596 -
Antibiotics (Basel)
Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia-An In Vitro and In Vivo Study. [Abstract]2022 Feb 1;11(2):192. PMID: 35203795
Levofloxacin sodium purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]
Determined minimum inhibitory concentrations (MICs) of Gepotidacin, Levofloxacin, Moxifloxacin, and Co-trimoxazole against S. maltophilia.
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Antimicrob Agents Chemother
Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo. [Abstract]2021 Feb 17;65(3):e01921-20. PMID: 33318002 -
-
Toxics
2025 Feb 5;13(2):122. PMID: 39997937 -
Microbiol Spectr
Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]2025 Oct 15:e0122125. PMID: 41090944 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 May 19:e0307424. PMID: 40387379 -
ACS Infect Dis
Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]2024 Apr 12;10(4):1327-1338. PMID: 38567846 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732 -
Eur J Clin Microbiol Infect Dis
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]2025 Sep 29. PMID: 41023358 -
-
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
PLoS One
In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. [Abstract]2024 Apr 18;19(4):e0298577. PMID: 38635685 -
Future Microbiol
2025 Oct 13:1-10. PMID: 41082411 -
Chin J Traumatol
The cytochrome P4501A1 (CYP1A1) inhibitor bergamottin enhances host tolerance to multidrug-resistant Vibrio vulnificus infection. [Abstract]2024 Jul 3:S1008-1275(24)00075-0. PMID: 38981821 -
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
-
-
-
-
Purity & Documentation
References
[1]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]
[2]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86. [Content Brief]
[3]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014. [Content Brief]
[4]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014. [Content Brief]
[5]. Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz